Equatorial Guinea vs Iraq: Average cost of multi drug-resistant tuberculosis treatment
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Iraq
1,500 constant 2022 US$
in 2024
Equatorial Guinea rank
34th
Iraq rank
34th
Average cost of multi drug-resistant tuberculosis treatment over time
- Equatorial Guinea
- Iraq
How they compare
Equatorial Guinea currently reports 1,500 constant 2022 US$ against 1,500 constant 2022 US$ in Iraq, a difference of 0 constant 2022 US$.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Iraq ahead.
Equatorial Guinea ranks 34th and Iraq ranks 34th of 92 countries.
Iraq has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Equatorial Guinea | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,000 constant 2022 US$ | 4,000 constant 2022 US$ | 3,000 constant 2022 US$ | Iraq |
| 2020s | 1,362 constant 2022 US$ | 2,300 constant 2022 US$ | 937.8 constant 2022 US$ | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Equatorial Guinea or Iraq?
- Equatorial Guinea, at 1,500 constant 2022 US$ against 1,500 constant 2022 US$ in Iraq as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Equatorial Guinea and Iraq?
- 0 constant 2022 US$, with Equatorial Guinea ahead.
- How many years of comparable data are there for Equatorial Guinea and Iraq?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Iraq rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Equatorial Guinea ranks 34th and Iraq ranks 34th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.